Novavax (NVAX) Leases: 2019-2024
Historic Leases for Novavax (NVAX) over the last 2 years, with Dec 2024 value amounting to $139.7 million.
- Novavax's Leases fell 12.79% to $139.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $139.7 million, marking a year-over-year decrease of 12.79%. This contributed to the annual value of $139.7 million for FY2024, which is 12.79% down from last year.
- According to the latest figures from Q4 2024, Novavax's Leases is $139.7 million, which was down 12.79% from $160.2 million recorded in Q4 2023.
- Novavax's Leases' 5-year high stood at $160.2 million during Q4 2023, with a 5-year trough of $7.8 million in Q4 2020.
- In the last 3 years, Novavax's Leases had a median value of $97.4 million in 2022 and averaged $108.4 million.
- As far as peak fluctuations go, Novavax's Leases spiked by 414.79% in 2021, and later declined by 12.79% in 2024.
- Quarterly analysis of 5 years shows Novavax's Leases stood at $7.8 million in 2020, then spiked by 414.79% to $40.1 million in 2021, then surged by 74.11% to $69.9 million in 2022, then skyrocketed by 129.37% to $160.2 million in 2023, then decreased by 12.79% to $139.7 million in 2024.
- Its Leases was $139.7 million in Q4 2024, compared to $160.2 million in Q4 2023 and $69.9 million in Q4 2022.